The Expander-2 trial randomly assigned men with BPH symptoms at 23 sites in the US and Canada to receive a temporary nitinol urethral implant, Urocross Expander, or a sham procedure.

These differences remained significant beyond the initial 90 days, indicating durable diagnostic sensitivity and facilitating earlier, risk-appropriate treatment decisions, which supports broader ...

Flexible packaging is already one of the most efficient packaging formats — and it’s on a fast track to better sustainability. Many solutions to improve end-of-life outcomes are already in play, even ...

Prostate and bladder cancers are among the most common urological malignancies worldwide. Traditional diagnostic approaches, including tissue biopsy, ...

Flex loans can offer quick access to cash, but there are potential risks Carrie Pallardy has more than nine years of experience writing about a range of topics, including healthcare and cybersecurity.